Roundtable Discussion: Leveraging Real-World Add-On Therapy Templates to Advance Combination Strategies in Neurodegenerative Diseases
2:00 pm - Wednesday 4th February 2026
- Criteria for selecting patient subgroups most likely to benefit from multi-mechanism approaches (e.g., stage of disease, biomarker profiles)
- Prioritizing clinically meaningful primary endpoints and complementary secondary measures to capture additive or synergistic effects
- Using established PD add-on protocols and emerging AD combination trials as models for endpoint selection and regulatory alignment
